U.S. markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
50.89+0.14 (+0.28%)
Al cierre: 04:00PM EST
50.83 -0.06 (-0.12%)
Fuera de horario: 08:00PM EST

Bristol-Myers Squibb Company

Route 206 & Province Line Road
Princeton, NY 08543
United States
609 252 4621
https://www.bms.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo34,100

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Giovanni Caforio M.D.Executive Chairman of the Board5.76MN/D1965
Dr. Christopher S. Boerner Ph.D.CEO & Director2.62MN/D1971
Mr. David V. ElkinsExecutive VP & CFO2.72M2.83M1968
Ms. Sandra Leung Esq.Executive VP & General Counsel2.66MN/D1961
Mr. Greg MeyersExecutive VP and Chief Digital & Technology OfficerN/DN/D1973
Mr. Timothy PowerVP & Head of Investor RelationsN/DN/DN/D
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerN/DN/DN/D
Ms. Ahn Amanda PooleExecutive Vice President & Chief Human Resources OfficerN/DN/D1975
Mr. Samit Hirawat M.D.Executive VP & Chief Medical Officer of Drug DevelopmentN/DN/D1969
Dr. Joseph J. Eiden Jr.Head of Medical AffairsN/DN/D1949
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York.

Gestión corporativa

La calificación ISS Governance QuickScore de Bristol-Myers Squibb Company a partir del 28 de febrero de 2024 es 2. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 2; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.